XBIT Stock Overview
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases.
No risks detected for XBIT from our risk checks.
XBiotech Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.40|
|52 Week High||US$12.64|
|52 Week Low||US$3.00|
|1 Month Change||-4.49%|
|3 Month Change||-16.26%|
|1 Year Change||-69.23%|
|3 Year Change||-69.42%|
|5 Year Change||-27.04%|
|Change since IPO||-85.03%|
Recent News & Updates
We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash WiselyOct 25
We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO CompensationJun 16
XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth PlansMay 11
Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) SharesMar 18
Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings PotentialJan 08
|XBIT||US Biotechs||US Market|
Return vs Industry: XBIT underperformed the US Biotechs industry which returned -7.4% over the past year.
Return vs Market: XBIT underperformed the US Market which returned -14.9% over the past year.
|XBIT Average Weekly Movement||6.2%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: XBIT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: XBIT's weekly volatility (6%) has been stable over the past year.
About the Company
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus.
XBiotech Inc. Fundamentals Summary
|XBIT fundamental statistics|
Is XBIT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|XBIT income statement (TTM)|
|Cost of Revenue||US$1.68m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.19|
|Net Profit Margin||-440.49%|
How did XBIT perform over the long term?See historical performance and comparison